[Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance Prediction]

Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):852-856. doi: 10.3779/j.issn.1009-3419.2017.12.10.
[Article in Chinese]

Abstract

More than 80% of lung cancer is non-small cell lung cancer (NSCLC), and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC. Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC, and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC. 18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy, and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances, by PET/CT imaging before and after treatment, to achieve dynamic monitoring, guide the therapy before treatment and treatment of sensitive population screening process, to achieve NSCLC EGFR-TKI precise treatment is essential.

肺癌80%以上为非小细胞肺癌(non-small cell lung cancer, NSCLC),表皮生长因子受体(epidermal growth factor receptor, EGFR)介导的信号通路与NSCLC发生发展密切相关。针对EGFR的小分子EGFR赖氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor, EGFR-TKI)被应用于NSCLC的临床治疗,正电子发射计算机断层显像(positron emission tomography/computed tomgraphy, PET/CT)能够无创地对NSCLC患者全身EGFR表达及突变状况进行连续动态监测。18F-FDG PET/CT显像对于EGFR活化突变、EGFR-TKI治疗疗效具有预测价值,并且能够在体直接观察到药物与全身肿瘤病灶EGFR靶向结合的具体情况,通过治疗前后的PET-CT显像,实现治疗前高敏人群筛选和治疗全过程的动态监测、治疗策略指导,对实现NSCLC的EGFR-TKI精准治疗至关重要。.

Keywords: EGFR; Lung neoplasms; Molecular imaging; PET/CT; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • ErbB Receptors / antagonists & inhibitors*
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Molecular Imaging / methods*
  • Molecular Targeted Therapy / adverse effects
  • Molecular Targeted Therapy / methods*
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • ErbB Receptors

Grants and funding

本文受天津市自然科学基金(No.17JCYBJC25100)和天津医科大学肿瘤医院人才启动基金(No.B1605)资助